Armata Pharmaceuticals, Inc. (ARMP)

NYSEAMERICAN: ARMP · IEX Real-Time Price · USD
5.25
-0.17 (-3.14%)
Jan 27, 2022 4:00 PM EST - Market closed
Market Cap142.20M
Revenue (ttm)3.99M
Net Income (ttm)-23.73M
Shares Out27.09M
EPS (ttm)-1.07
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume55,394
Open5.43
Previous Close5.42
Day's Range5.05 - 5.68
52-Week Range2.82 - 6.50
Beta-0.11
AnalystsStrong Buy
Price Target8.00 (+52.4%)
Earnings Daten/a

About ARMP

Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for the treatment of Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing propriet...

IndustryBiotechnology
CEOTodd Patrick
Employees59
Stock ExchangeNYSEAMERICAN
Ticker SymbolARMP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ARMP stock is "Strong Buy." The 12-month stock price forecast is 8.00, which is an increase of 52.38% from the latest price.

Price Target
$8.00
(52.38% upside)
Analyst Consensus: Strong Buy

News

Recent Price Trend in Armata Pharmaceuticals, Inc. (ARMP) is Your Friend, Here's Why

Armata Pharmaceuticals, Inc. (ARMP) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that pa...

3 weeks ago - Zacks Investment Research

Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs

MARINA DEL REY, Calif., Jan. 5, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific ba...

3 weeks ago - PRNewsWire

Wall Street Analysts Believe Armata Pharmaceuticals, Inc. (ARMP) Could Rally 47%: Here's is How to Trade

The mean of analysts' price targets for Armata Pharmaceuticals, Inc. (ARMP) points to a 46.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agree...

1 month ago - Zacks Investment Research

Armata Pharmaceuticals Provides Regulatory and Clinical Update Reflecting Sustained Progress Across Key Phage Therape...

MARINA DEL REY, Calif., Nov. 18, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific b...

2 months ago - PRNewsWire

What Makes Armata Pharmaceuticals, Inc. (ARMP) a New Buy Stock

Armata Pharmaceuticals, Inc. (ARMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago - Zacks Investment Research

Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Tops Revenue Estimates

Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 15.38% and 23.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th...

2 months ago - Zacks Investment Research

Armata Pharmaceuticals Announces Third Quarter Results and Provides General Corporate Update

MARINA DEL REY, Calif., Nov. 10, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage t...

2 months ago - PRNewsWire

Armata Pharmaceuticals, Inc. (ARMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Armata Pharmaceuticals, Inc. (ARMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Armata Pharmaceuticals to Present at the 2021 World Antimicrobial Resistance Congress

MARINA DEL REY, Calif., Nov. 4, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage t...

2 months ago - PRNewsWire

Armata Enters Lease to Build State-of-the-Art R&D and GMP Manufacturing Facility

MARINA DEL REY, Calif., Nov. 2, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific ba...

2 months ago - PRNewsWire

Cystic Fibrosis Foundation Makes Equity Investment in Armata Pharmaceuticals

MARINA DEL REY, Calif., Oct. 28, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific b...

2 months ago - PRNewsWire

Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

MARINA DEL REY, Calif., Sept. 8, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage t...

4 months ago - PRNewsWire

Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Tops Revenue Estimates

Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 0.00% and 42.44%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Armata Pharmaceuticals Announces Second Quarter Results and Provides General Corporate Update

MARINA DEL REY, Calif., Aug. 12, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage t...

5 months ago - PRNewsWire

Will Armata Pharmaceuticals, Inc. (ARMP) Report Negative Q2 Earnings? What You Should Know

Armata Pharmaceuticals, Inc. (ARMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Armata Pharmaceuticals Announces Chief Executive Officer Transition

MARINA DEL REY, Calif., Aug. 2, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on pathogen-specific ba...

5 months ago - PRNewsWire

Armata Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference

MARINA DEL REY, Calif. , July 7, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage t...

6 months ago - PRNewsWire

Armata Pharmaceuticals Announces First Quarter Results and Provides General Corporate Update

MARINA DEL REY, Calif., May 13, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage th...

8 months ago - PRNewsWire

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Armata Pharmaceuticals Inc. for Potential Breaches ...

NEW YORK, May 13, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty cla...

8 months ago - PRNewsWire

Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Results and Provides General Corporate Update

MARINA DEL REY, Calif., March 18, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage ...

10 months ago - PRNewsWire

Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $20 Million Private Placement with Innoviva

MARINA DEL REY, Calif., March 17, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage ...

10 months ago - PRNewsWire

Armata Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference

MARINA DEL REY, Calif., March 16, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage ...

10 months ago - PRNewsWire

Notable Insider Buys Seen In The Past Week: Green Brick, Intel, Teledyne And More

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

11 months ago - Benzinga

Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company's Bacteriophage Develop...

MARINA DEL REY, Calif., Jan. 27, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage t...

1 year ago - PRNewsWire

Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors

MARINA DEL REY, Calif., Dec. 9, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage t...

1 year ago - PRNewsWire